License and Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2020

Summary of Revenues by Collaboration and by Category of Revenue

The following table summarizes details of revenues by collaboration and by category of revenue:

			Year Ended December 31,
Revenues recognized:	Over time	Point in time	2020		2019		2018
Gilead license to zimberelimab		*	$	55,096	$	-	$	-
Gilead access rights related to the    Company's research and    development pipeline	*			15,421		-		-
Taiho license to zimberelimab		*		-		8,000		-
Taiho license to etrumadenant		*		-		-		3,000
Taiho collaboration agreement	*			7,000		7,000		5,353
Total collaboration and license    revenue			$	77,517	$	15,000	$	8,353

Summary of Revenue Recognized as a Result of Changes in Deferred Revenue

The Company recognized the following revenue as a result of changes in the deferred revenue balance during the period below (in thousands):

	Year Ended December 31,
Revenue recognized in the period from:	2020		2019		2018
Amounts included in deferred revenue    at the beginning of the period	$	7,000	$	7,000	$	5,353
Performance obligations satisfied in    previous period		-		-		-

Schedule of Payments Allocated to Performance Obligations

At the transaction closing date, these payments were allocated to the performance obligations identified as follows:

	Amount
Allocation of transaction price
Upfront cash consideration	$	175,000
Payment for access rights related to the    Company's research and development pipeline		100,000
Premium from Stock Purchase Agreement		90,600
Total transaction price allocated to revenue	$	365,600
Allocation to performance obligations
Zimberelimab license	$	55,096
Etrumadenant option		126,960
Domvanalimab option		36,728
Access rights related to the Company's research    and development pipeline		137,113
Development and commercialization services for    zimberelimab		9,703
Total	$	365,600

Gilead and Taiho

Summary of Revenues

The following table summarizes the revenues received as a result of the Company’s collaboration agreements with Gilead Sciences, Inc. (Gilead) and Taiho Pharmaceutical Co., Ltd. (Taiho):

	Year Ended December 31,
	2020		2019		2018
License revenue	$	55,096	$	8,000	$	3,000
Collaboration revenue		22,421		7,000		5,353
Collaboration and license revenue	$	77,517	$	15,000	$	8,353